Trials / Not Yet Recruiting
Not Yet RecruitingNCT05714683
Regulatory Post Marketing Surveillance (rPMS) Study of Rybelsus (Oral Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea
A Multi-centre, Prospective, Open-label, Single-arm, Non-interventional, Regulatory Post Marketing Surveillance (rPMS) Study of Rybelsus® (Oral Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea
- Status
- Not Yet Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 600 (estimated)
- Sponsor
- Novo Nordisk A/S · Industry
- Sex
- Female
- Age
- 19 Years
- Healthy volunteers
- —
Summary
The aim of this study is to assess the safety and effectiveness of Rybelsus initiated according to label in adults with Type 2 Diabetes Mellitus (T2DM) under routine clinical practice conditions. Participants will get Rybelsus as prescribed by study doctor. The study will last for about 26 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Semaglutide | All participants will be treated with oral semaglutide for 26 weeks according to routine clinical practice at the discretion of the treating physician according to the label approved by MFDS. The prescription of semaglutide will be separated from the decision to include the participant in the study. |
Timeline
- Start date
- 2025-12-31
- Primary completion
- 2026-10-30
- Completion
- 2026-10-30
- First posted
- 2023-02-06
- Last updated
- 2025-12-05
Source: ClinicalTrials.gov record NCT05714683. Inclusion in this directory is not an endorsement.